Modulation of an individual's gut microbiome to address osteoporosis and bone disease
AssigneeSeed Health, Inc.
InventorsTye Jensen, Joseph E. Kovarik
Life of this patent
Estimating the term…
Abstract
Various embodiments of the present invention are directed to the field of treating and preventing osteoporosis, with particular embodiments directed to a method of ameliorating, treating, or preventing osteoporosis in a human subject employing tomatidine, xylitol, rapamycin, etc., as well as modifying an individual's microbiome to reduce the likelihood of osteoporosis.
Claims17
A method for reducing the likelihood of developing osteoporosis in an individual human being, comprising:
- providing via oral administration a population of beneficial bacteria that produce butyrate, said beneficial bacteria encapsulated in a shell that protects said beneficial bacteria from contact with an individual's stomach acid, said beneficial bacterial comprising at least one of Coprococcus, Roseburia, Bifidobacterium, Faecalibacterium prausnitzi and Akkermansia muciniphila;
- administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual human being and, administering to the individual beneficial bacteria of one of the genera Collinsella, Megasphaera, Agathobaculum, Mediterraneibacter, Clostridium XIV, and Dorea.
A method for reducing the likelihood of developing osteoporosis in an individual human being, comprising:
- increasing the abundance of short chain fatty acid (SCFA) producing bacteria and their metabolites by providing, via oral administration, a population of beneficial bacteria that produce one of butyrate, acetate, and propionate, said beneficial bacteria encapsulated in a shell that protects said beneficial bacteria from contact with an individual's stomach acid, said beneficial bacterial comprising at least one of Coprococcus, Roseburia, Bifidobacterium, Faecalibacterium prausnitzi and Akkermansia muciniphila;
- administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual human being, wherein an amount of SCFA produced by said beneficial bacteria increases circulating insulin-like growth factor-1 to stimulates osteogenesis and, providing to the individual at least about 300 mg of tributyrin.
A method for reducing the likelihood of developing osteoporosis in an individual, comprising:
- orally providing to an individual beneficial bacteria comprising at least one of Coprococcus, Roseburia, Bifidobacterium, Faecalibacterium prausnitzi and Akkermansia muciniphila wherein said beneficial bacteria are encapsulated in a shell that protects said beneficial bacteria from contact with an individual's stomach acid;
- administering fiber to the individual to maintain a therapeutically effective amount of the beneficial bacteria in the gut of the individual;
- wherein said beneficial bacteria are effective to modulate the individual's gut microbiome in a manner that reduces osteoporosis;
- and administering at least 300 mg of tributyrin to the individual.
Dependencies are inferred from the claim text.